Objective Serotonergic psychedelics are re-emerging as potential novel treatments for
several psychiatric disorders including major depressive disorder. The Canadian Network …

The current meta-analysis examined the effects of psilocybin in combination with behavioral
interventions on anxiety and depression in samples with elevated symptoms. Across four …

Abstract Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is an indole-based
secondary metabolite produced by numerous species of mushrooms. South American Aztec …

Background Psilocybin therapy is receiving attention as a mental health intervention with
transdiagnostic potential. In line with psychotherapeutic research, qualitative research has …

Depression is a common mental health issue that affects 280 million people in the world with
a high mortality rate, as well as being a leading cause of disability. Psychopharmacological …

The psychedelic psilocybin is being investigated for the treatment of depression and anxiety.
Unclear is whether antidepressant treatments interact with psilocybin. The present study …

Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies
for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin's …

Introduction Psilocybin is a psychedelic tryptamine that has shown promise in recent clinical
trials for the treatment of depression and substance use disorders. This open-label study of …

Psilocybin-containing mushrooms have been consumed by various cultures in many
different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains …

Psilocybin and other 5-hydroxytryptamine 2A agonist classic psychedelics have been used
for centuries as sacraments within indigenous cultures. In the mid-twentieth century they …